Abiraterone Acetate and Radium-223 in Castrate-Resistant Prostate Cancer: Finding the Right Treatment at the Right Time

Chuck Ryan's presentation on Abriaterone Acetate and Radium-223 and finding the right treatment at the right time for the right patient.  This discussion is lead by reviewing a patient case study and the practical considerations in the use of novel hormonal agents in the post-ADT setting.  Dr. Ryan provides take home points for proactive metastatic castration-restistant prostate thearpy and benefits of radium-223 for life prolongation. 

Biography

Charles J. Ryan, MD is Professor of Clinical Medicine and Urology and the Clinical Program Leader for Genitourinary Medical Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center. He received his MD from the University of Wisconsin in Madison and completed his residency in internal medicine at the University of Wisconsin Hospital and Clinics, where he also served as Chief Resident. He completed a fellowship in medical oncology in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and the Joan and Sanford I. Weill Medical College of Cornell University in New York.